CSL Behring offers new dosage strength of Helixate FS in U.S.

Hemophilia A patients who require high doses of Helixate® FS, Antihemophilic Factor (Recombinant), can now benefit from greater convenience in administering their treatment, thanks to a new 3000 IU (international unit) dosage strength. CSL Behring announced today that this new dosage strength is available in the U.S., allowing many patients to reduce reconstitution time by eliminating the need to mix and pool multiple vials of Helixate FS.

“Treatment compliance and adherence are two challenges for people with hemophilia A and the healthcare professionals who help them manage their condition,” said Garrett E. Bergman, M.D. Senior Director of Medical Affairs, U.S. Commercial Operations at CSL Behring. “The new 3000 IU dosage strength for Helixate FS is one more advancement that will encourage compliance with prescribed treatment by helping to shorten the time many patients spend infusing.”

All dosage strengths of Helixate FS, including the new 3000 IU, are packaged with the Mix2Vial™. The Mix2Vial is an easy-to-use, plastic, needle-free transfer device with a built-in filter. Treatment can also be complemented by using HeliTraxSM, a wireless electronic data management system that can help improve patient-treatment team communications and therapy management.

“As an athlete, I lead an extremely active and busy lifestyle,” said Jesse Schrader, a patient with hemophilia A, who plays competitive baseball. “The 3000 IU dosage strength for Helixate FS will help me save time, as I’ll only have to use one vial to receive my therapy.”

To provide dosing flexibility to healthcare professionals and people who are managing their hemophilia A, Helixate FS comes in a variety of dosage strengths: 250 IU, 500 IU, 1000 IU, 2000 IU and the new 3000 IU.

With more than 2.5 billion units infused to date, Helixate FS has been shown to be safe and effective in clinical studies as well as in post marketing use in the hemophilia community. For more information about Helixate FS, please visit www.HelixateFS.com or call CSL Behring Consumer Affairs at 1-888-508-6978.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
You might also like... ×
New Europe-wide report explores the impact of AI on healthcare practitioners